Compare ADMA Biologics Inc (ADMA) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.85. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ADMA | TMF | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $44.14 |
52-Week Low | $7.60 | $30.59 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $31.43 with a modest 0.67% daily gain. Technical indicators show a bearish bias overall, with moving averages signaling caution, though oscillators are neutral. The ETF, which provides 3x leveraged exposure to long-duration U.S. Treasuries, faces significant volatility due to its daily leverage reset mechanism. Recent news highlights its high-risk nature, with one article noting a substantial decline from a $10,000 investment five years ago to approximately $1,527, underscoring the perils of long-term holding.
The outlook for TMF is highly speculative and tied to interest rate movements. While some see opportunity at perceived lows in the bond market, the consensus warns it is unsuitable for long-term investment. Primary risks include extreme volatility from daily leverage resets and adverse shifts in Treasury yields. It remains a tactical, short-term instrument for experienced traders, not a core portfolio holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
